Exact Sciences honored as 2016 BIG Award Company of the Year in Health Care
Exact Sciences Corp. announced that the company received the Business Intelligence Group’s 2016 Company of the Year BIG Award for Business in the Health Care category....
Exact Sciences Corp. announced that the company received the Business Intelligence Group’s 2016 Company of the Year BIG Award for Business in the Health Care category....
Exact Sciences Corp., a Madison maker of molecular diagnostic tests, said its flagship test for colon cancer has been added to a data set that is widely used to measure the quality of health plans....
Cellular Dynamics International, Madison, has created a company, Opsis Therapeutics, to develop treatments that could restore vision to patients with diseases of the retina....
Reuters ranks the University of Wisconsin System 13th on its list of the "The World's Most Innovative Universities"....
Amgen, one of the world's leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start with the potential for another $600 million or more in the future....
With spin-off investments Grail and Helix, and a new software-savvy CEO, Illumina is poised to make DNA an even bigger part of your life....
Governor Scott Walker joined Bunker Labs Wisconsin, Inc. to announce the launch of The Muster-Madison, a daylong event at the Wisconsin State Capitol that highlights interaction that will inspire, educate, and connect military veteran entrepreneurs to the startup community, business leaders, and each other....
The Madworks Seed Accelerator is now seeking startups to participate in its Fall 2016 program. Participants receive $5,000 for completing the 10-week session....
The University of Wisconsin-Madison ranked 14th among all universities in the world in a count of how many venture capital-backed entrepreneurs it has spawned, according to a report by Pitchbook Data....
Arrowhead Pharmaceuticals has initiated a Phase 2 clinical trial for its drug candidate aimed at treating rare liver diseases associated with alpha-1 antitrypsin (AAT) deficiency....